20 May 2015

CRISPR Therapeutics


CRISPR Therapeutics conducted a Series A financing of CRISPR Therapeutics. CRISPR Therapeutics is a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines. The financing round is led by SR One and includes new investors New Enterprise Associates (NEA) and Abingworth, alongside the founding investor, Versant Ventures.


Walder Wyss AG, led by Alexander Gutmans (Partner, Corporate/M&A), advises the investors on the Swiss law aspects together with Wilson Sonsini Goodrich & Rosati as Lead Counsel.

News

News

20 May 2015

CRISPR Therapeutics

CRISPR Therapeutics conducted a Series A financing of CRISPR Therapeutics. CRISPR Therapeutics is a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines. The financing round is led by SR One and includes new investors New Enterprise Associates (NEA) and Abingworth, alongside the founding investor, Versant Ventures.


Walder Wyss AG, led by Alexander Gutmans (Partner, Corporate/M&A), advises the investors on the Swiss law aspects together with Wilson Sonsini Goodrich & Rosati as Lead Counsel.